Eli Lilly, Enova Emerge as Rotation Picks as Healthcare Gains 14% and Financials Rise 10%
Updated
Updated · CNBC · Jul 29
Eli Lilly, Enova Emerge as Rotation Picks as Healthcare Gains 14% and Financials Rise 10%
2 articles · Updated · CNBC · Jul 29
Summary
Eli Lilly and Enova International were singled out as potential leaders as money rotates into healthcare and financials while the S&P 500 stays stuck in a summer consolidation.
Healthcare has climbed more than 14% and financials more than 10% since June, versus lagging technology, suggesting investors are favoring either defensive groups or the market’s next leadership cohort.
Lilly broke above roughly $1,200 in July and is now testing that breakout in a tight flag; the setup is backed by 31% expected revenue growth and 43% EPS growth this fiscal year, with August earnings seen as a catalyst.
Enova has already confirmed a bullish flag breakout on rising volume after a 136% 12-month return, trading at 13.1 times forward earnings with projected revenue growth of 18% and 22% over the next two fiscal years.
The broader backdrop remains a 'coiled spring' market: the S&P 500 is only 3% below its June 2 peak, and the sector winners during that pause may signal where the next breakout leadership emerges.
Is the S&P 500’s summer stall quietly handing market leadership to healthcare and financials, with Eli Lilly and Enova emerging as the clearest signals?
Can Eli Lilly’s post-breakout strength and Enova’s surge to new highs survive earnings, valuation pressure, and regulatory scrutiny?